Ribociclib Plus Letrozole in Italian Male Patients with Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Case Studies of Phase 3b CompLEEment-1 Trial

Roberta Caputo1 Dipartimento di Senologia, Istituto Nazionale Tumori Fondazione Pascale, IRCCS, Naples, ItalyCorrespondence[email protected]
View further author information

Alessandra Fabi2 Dipartimento di Oncologia Medica, Istituto Nazionale Tumori Regina Elena - Istituti Fisioterapici Ospitalieri, Rome, Italy;3 Precision Medicine in Breast Cancer, Department of Woman and Child Health and Public Health, Scientific Directorate, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Roma, ItalyView further author information

Emanuela Romagnoli4 U.O.C. Oncologia, Presidio Ospedaliero di Macerata, Macerata, ItalyView further author information

Editta Baldini5 Director of the U.O.C. Medical Oncology, San Luca Hospital via Guglielmo Lippi Francesconi, Lucca, ItalyView further author information

Donatella Grasso6 Oncology, Novartis Farma SpA, Origgio, ItalyView further author information

Nicola Fenderico6 Oncology, Novartis Farma SpA, Origgio, Italy